Acute Lymphoblastic Leukaemia Recurrent Active Not Recruiting Phase 2 Trials for Dasatinib (DB01254)

Also known as: Acute, recurrent Lymphoblastic Leukaemia / Acute, recurrent Lymphoblastic Leukemia / Recurrent Acute lymphoblastic leukemia / Acute, relapsed Lymphoblastic Leukemia / Relapsed Acute Lymphoblastic Leukemia / Acute lymphoblastic leukemia recurrent / Relapsed ALL / Acute lymphocytic leukemia recurrent / Acute lymphocytic leukaemia recurrent

IndicationStatusPhase
DBCOND0083559 (Acute Lymphoblastic Leukaemia Recurrent)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00390793Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.Treatment